文献速递胸部肿瘤

通过胸腔积液游离DNA测序增强非小细胞肺癌可靶向突变检测:一项前瞻性研究

Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study.
PubMed 文献 · Eur J Cancer · 2025-01-07

这项前瞻性研究纳入50例新诊断的晚期非小细胞肺癌合并恶性胸腔积液患者,比较胸腔积液游离DNA二代测序、胸腔积液细胞沉淀RT-PCR及临床组织基因检测对可靶向突变的检出率。胸腔积液游离DNA二代测序在44例(88%)中检出可靶向突变,高于胸腔积液细胞沉淀Sanger测序的39例(78%)和临床组织基因检测的33例(66%),差异有统计学意义(P = 0.031)。

要点

  • 50例患者中45例(90%)存在可靶向突变,胸腔积液游离DNA二代测序检出44例(88%)。
  • 胸腔积液游离DNA二代测序检出率高于临床组织基因检测的33例(66%),P = 0.031。
  • 胸腔积液游离DNA二代测序检出率在M1a至M1c各分期中保持较高水平。

核心结论

  • 胸腔积液游离DNA基因分型对非小细胞肺癌患者具有临床适用性,可作为分子检测的额外来源。
  • 将胸腔积液游离DNA二代测序分析纳入基因检测可提高诊断率,并有助于在临床实践中识别可靶向突变。

研究设计与样本

  • 前瞻性研究,纳入新诊断的晚期非小细胞肺癌合并恶性胸腔积液患者50例。
  • 采集胸腔积液样本进行游离DNA二代测序分析;同时提取胸腔积液细胞沉淀RNA进行逆转录聚合酶链反应检测临床相关可靶向突变,并经Sanger测序确认。
  • 分析胸腔积液细胞沉淀逆转录聚合酶链反应与胸腔积液游离DNA二代测序之间的一致性。

主要发现

  • 患者中位年龄68.5岁,女性与男性比例为29:21,大多数患者(74%)为非吸烟者。
  • 45/50例患者(90%)存在可靶向突变,包括EGFR外显子19缺失(24%)、EGFR L858R突变(36%)、HER2外显子20插入(10%)、ROS1重排(4%)、EGFR外显子20插入(2%)、ALK重排(4%)、RET重排(2%)、KRAS G12C突变(2%)和CD74-NRG1融合(2%)。
  • 50例入组患者中,胸腔积液游离DNA二代测序检出可靶向突变44例(88%),胸腔积液细胞沉淀Sanger测序检出39例(78%),临床组织基因检测检出33例(66%),P = 0.031。
  • 胸腔积液游离DNA二代测序对可靶向突变的检出在M1a至M1c各分期中保持较高水平。

临床怎么用

  • 胸腔积液游离DNA基因分型对非小细胞肺癌患者具有临床适用性,可作为分子检测的额外来源。
  • 将胸腔积液游离DNA二代测序分析纳入基因检测可提高诊断率,并有助于在临床实践中识别可靶向突变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inadequate tumour samples often hinder molecular testing in non-small cell lung cancer (NSCLC). Plasma-based cell-free DNA (cfDNA) sequencing has shown promise in bypassing these tissue limitations. Nevertheless, pleural effusion (PE) samples may offer a richer cfDNA source for mutation detection in patients with malignant PE. METHODS: This prospective study enrolled newly diagnosed advanced NSCLC patients with malignant PE. PE samples were collected for cfDNA NGS analysis. Meanwhile, PE cell pellet RNA was extracted for reverse transcription polymerase chain reaction (RT-PCR) for clinically relevant actionable mutations and then confirmed by Sanger sequencing. The concordance between PE cell pellet RT-PCR and PE cfDNA NGS analyses was analysed. RESULTS: Fifty patients were enrolled. The median age was 68.5 years, and the female-to-male ratio was 29:21. Most patients (74 %) were non-smokers. Notably, 45/50 patients (90 %) had actionable mutations, including EGFR exon 19 deletions (24 %), EGFR L858R mutations (36 %), HER2 exon20 insertions (10 %), ROS1 rearrangements (4 %), EGFR exon20 insertions (2 %), ALK rearrangements (4 %), RET rearrangements (2 %), KRAS G12C mutations (2 %), and CD74-NRG1 fusions (2 %). Among the 50 enrolled patients, actionable mutations were detected in 44 (88 %) by PE cfDNA NGS, 39 (78 %) by PE cell pellet Sanger sequencing, and 33 (66 %) by clinical tissue genetic testing (P = 0.031). The detection of actionable mutations from PE cfDNA NGS remained consistently high across M1a to M1c stages. CONCLUSIONS: PE cfDNA genotyping has clinical applicability for NSCLC patients and can serve as an additional source for molecular testing. Incorporating PE NGS cfDNA analysis into genetic testing enhances diagnostic yield and aids in identifying actionable mutations in clinical practice.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wang HY, Liao WY, Ho CC, et al. Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study. Eur J Cancer. 2025. PMID: 39799785. doi:10.1016/j.ejca.2025.115224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。